Russia increases state procurement of Gilead's Veklury

6 January 2022

Russia is increasing state procurement of Veklury (remdesivir), a drug against COVID-19, which is produced by US biotech Gilead Sciences (Nasdaq: GILD) - due to interruptions of supplies of its generic from local firm Pharmsynthez to domestic market.

Since the middle of 2021 the supplies of Veklury to Russia have been insignificant, while most of the market was taken by Pharmsynthez’ Remdeform (remdesivir).

Its appearance in the Russian market, however, caused a scandal, when in January of last year, the Russian government, allowed Pharmsynthez to produce it and supply under government contracts until the end of 2021. Such permission was provided to the Russian company despite valid Gilead patents. For its part, Gilead challenged the authorities' decision in Russian courts, but lost the case in May of 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK